Latest News
Cambridge, UK. 20 May 2019. STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing to […]
Alcester, Warwickshire, UK. 15 April 2019. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the […]
Hamilton, Ontario and Dublin, Ireland. April 2nd 2019. Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led […]
Boston, Massachusetts & Hamilton, Ontario. February 19, 2019. Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was dosed in a Phase 1, first-in-human clinical trial […]
Dublin, Ireland. 30 January 2019. Seroba portfolio company, Labcyte, has been acquired by Beckman Coulter Life Sciences, part of the larger Danaher Corporation which generates approximately $6.5 billion in annual revenue. Labcyte is best known for […]
Ireland and California, USA. January 08, 2019. Seroba’s portfolio company, PQ Bypass, Inc., a medical device company dedicated to advancing treatment options for patients with peripheral arterial disease (PAD), has entered into an agreement that provides […]
